Latest news with #Adela
The Star
3 days ago
- Entertainment
- The Star
A heartfelt tribute to the German artist who called Malaysia home
Many artists from abroad have found a home in Malaysia, but the late Askandar Unglehrt (1943–2022) made it his own by embracing its culture with heart and curiosity. He once summed up his creative vision with disarming clarity: 'I observe the East with one eye and the West with the other. A 'Third Eye', which is my creative eye, combines the fragments of my observations into experiences of their own.' His philosophy shaped his art – bridging cultures, reframing traditions and weaving them into something entirely his own, laced with mischievous wit. The late Unglehrt's tribute show at Harta Space offers a survey of his collage works and archival material. Photo: The Star/Filepic The German-born artist and academic, who made Penang his home for more than 50 years, brought a distinctive voice to Malaysia's art scene. Before arriving on these shores, he studied at the Sorbonne in Paris in the late 1960s, majoring in French and German, and wrote his PhD dissertation on the poetry of Jean Arp, the German-French sculptor, painter and poet. Unglehrt began teaching both French and German at Universiti Sains Malaysia, Penang in 1972. Adela, co-curator of the exhibition, shares insights into her father's art practice and his unique East-West perspective. Photo: The Star/M. Irsyad Alongside his academic work, he developed a highly recognisable collage practice, fusing Western art styles with locally sourced materials such as magazines, newspaper clippings and advertisements. In the spirit of Merdeka month, the public can now revisit his legacy through A Third Eye: A Tribute To Askandar Unglehrt, on view at Harta Space in Ampang, Selangor, until Aug 31. His work was last officially showcased in the Klang Valley in 2017, in the solo exhibition Walau Bagaimanapun at Suma Orientalist. Lovingly assembled This tribute at Harta Space – featuring works Unglehrt created between 1973 and 2003 – is co-curated by his daughter Adela, who has overseen the care and preservation of his artworks. The show's other curator is Ricardo Chavez Tovar, a Penang-based artist and academic from Mexico. Unglehrt's 'Malaysia / World The Great Rehearsal' (1990) captures the artist's local culture fascination in a collage work. Photo: Harta Space Unglehrt's works have been showcased at the National Art Gallery in Kuala Lumpur and are held in the collections of the Penang State Art Gallery, Singapore Art Museum, Galeri Petronas and other notable institutions. A Third Eye features 62 works, ranging from acrylic on canvas and prints to magazine pieces and collages on anonymous paintings. 'While many would know him as an artist in Penang, he was more known as an art collector in the Klang Valley. The exhibition will take visitors through a timeline of his artistic journey and what influences he had over the years. Some were taken from private collections, and some of them, I've rediscovered this year, buried in storage,' says Adela in a recent interview. She recalls unearthing unexpected treasures while preparing the show. Tovar (right) and curator Unglehrt examine one of Tovar's works in Penang, 2006. At Harta Space, Tovar co-curated the German-born artist's tribute show. Photo: The Star/Filepic 'I knew they existed, as his main technique was manual collage, and he would re- photograph the finished pieces. We found film strips and other records that give an insight into his process, showing what he was referencing at the time,' she explains. Over the years, Malaysian influences and pop culture references began to weave into his compositions in the 1980s. 'This was in an era where Star Wars was a craze, and he used popular symbols like Superman, Charlie Chaplin, Yoda and others. He would also buy old windows from flea markets, using them as a canvas. 'Sometimes he painted over anonymous works he found there, giving them a completely new context,' she says. Sambal on the side Visitors will see these ideas most clearly in his 'Malaysiana' series. One standout, Mona Malaysia (1989), reimagines the iconic Mona Lisa with a distinctly Malaysian twist – her serene face framed by a Muslim headdress. Unglehrt's work titled 'Consulting Yoda' (1983-1984). Photo: Harta Space 'This also reflects the rise of Muslim women in (local) universities at the time. He often responded to social shifts he observed around him. Nowadays there are digital methods of collaging, but his work was painstakingly done by hand,' says Adela. Unglehrt's personal life also shaped his art. Starting a family in the early 1970s in Penang with his wife, Tengku Idaura Tengku Ibrahim, who has Kelantanese roots, meant Unglehrt spent extended periods on the East Coast, immersing himself in its landscapes and traditions. 'He explored the scenery, the everyday commentaries on Malaysian life, and even popular TV shows that began to run at the time,' says Adela. Unglehrt's 'The Short Cut' (1995) is a collage on a painting featuring Fantastic Four's The Thing riding a motorcycle through a kampung. Photo: Harta Space Works such as The Great Malaysian Sunset (1989) playfully place Darth Vader in a film strip sequence of a tranquil beach in Bachok, Kelantan, while The Short Cut (1995) sends the Fantastic Four's The Thing roaring down a kampung road on a motorcycle. Together, these pieces capture Unglehrt's knack for blending pop culture with the Malaysian landscape, creating images that are at once humorous and thought-provoking. 'This exhibition serves as a precursor to a more comprehensive retrospective planned for 2026–2027, which will examine his legacy and continued relevance in Malaysian contemporary art. "We also wish to bring a larger collection to Penang where he spent most of his time in Malaysia,' concludes Adela. A Third Eye: A Tribute To Askandar Unglehrt is showing at Harta Space in Ampang, Selangor until Aug 31. Free admission. Closed on Mondays.
Yahoo
30-05-2025
- Business
- Yahoo
Adela to Present Data Highlighting Ability of its Tissue-Agnostic Test for MRD Detection and Response Monitoring to Predict Progression and Identify Non-Responders to Immunotherapy in Solid Tumors at the 2025 ASCO Annual Meeting
FOSTER CITY, Calif., May 30, 2025 /PRNewswire/ -- Adela, Inc., an innovator in blood testing for molecular residual disease (MRD) monitoring and early cancer detection through a proprietary genome-wide methylome enrichment technology, is presenting results of two studies demonstrating the ability of its MRD test to predict progression and identify non-responders to immunotherapy at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting from May 30 – June 3, 2025. "In patients with advanced cancer receiving immunotherapy, it can be challenging to differentiate true progression from pseudoprogression during early treatment cycles based on imaging," said Lillian Siu, MD, FRCPC, Medical Oncologist and Senior Scientist, Princess Margaret Cancer Centre, University Health Network. "To better identify non-responders and guide timely treatment adjustments, more reliable response assessment tools are needed. Methylation-based circulating tumor DNA (ctDNA) technology shows promise in these regards." The ability of Adela's test to identify progression in patients treated with immunotherapy was demonstrated in two studies. The first study included banked samples from 64 patients with advanced head & neck, breast, ovarian, melanoma, or other solid tumors who received pembrolizumab. Blood samples were collected pre-treatment and prior to initiation of cycle 3 of treatment. A decrease in ctDNA from the pre-treatment blood draw to the pre-cycle 3 blood draw was associated with a significantly better PFS [hazard ratio (HR) of 0.28 (0.15, 0.49); p<0.0001] and OS [HR 0.42 (0.24, 0.76); p=0.003]. "These results show promise in assessing response to immunotherapy early in a patient's course of treatment," said Enrique Sanz-Garcia, MD, Medical Oncologist and Clinician-Investigator at Princess Margaret Cancer Centre, University Health Network. "Identifying non-response earlier can support timely treatment decisions and help avoid unnecessary toxicity." The second study included banked samples from 63 patients with stage III/IV non-small cell lung cancer treated with definitive chemoradiation followed by consolidative durvalumab (stage III) or with PD-1 inhibitors +/- chemotherapy (stage IV). Blood samples were collected pre-treatment, 2-4 weeks after treatment initiation and approximately 6-8 weeks thereafter until progression. Patients with a positive MRD test showed significantly worse PFS than those who tested negative (HR 4.8; 95% CI, 2.1-10.8; P < 0.0001). "Together, these two studies demonstrate the potential of Adela's tissue-agnostic test to predict outcomes and support clinical decision-making for patients receiving immunotherapy across a range of cancer types," said Dr. Anne-Renee Hartman, Chief Medical Officer at Adela. "Because tumor tissue is often unavailable in patients with advanced cancer, Adela's blood-only, tissue-free approach offers a universally accessible solution for this population." Adela's MRD test based on its genome-wide methylome enrichment platform is currently available to biopharmaceutical companies and other investigators for Research Use Only (RUO), including for biomarker discovery and drug development. Adela plans to commercialize the test in 2025 for use in patients who have received curative intent treatment for head & neck cancer, regardless of HPV status, to detect recurrence earlier and help guide treatment decision-making. Presentation Details Abstract #8550: Identification of immunotherapy early treatment failure in non-small cell lung cancer (NSCLC) using a novel cell-free DNA (cfDNA) tissue-agnostic genome-wide methylome enrichment assay Dr. Tuan Hoang1 Hall A, Poster Board: 30 Saturday May 31, 2025 1:30 PM-4:30 PM CDT Abstract # 2545: Validation of an optimized tissue-agnostic genome-wide methylome enrichment assay to predict clinical outcomes in patients treated with pembrolizumab DR. Enrique Sanz-Garcia1 Hall A, Poster Board: 192 Monday June 2, 2025 1:30 PM-4:30 PM CDT About Adela Adela is developing best-in-class technology to accelerate the diagnosis and improve the management of cancer through blood tests for minimal residual disease (MRD) monitoring and multi-cancer early detection (MCED). Adela's blood-based, tissue-free product ensures universal accessibility to MRD testing for patients with cancer, eliminating any dependency on tumor tissue availability. Adela's approach efficiently captures extensive, biologically-relevant genomic information from the methylome, providing greater opportunity to detect cancer signals in the blood compared to platforms that target a smaller set of genomic regions. Adela's first product utilizing this genome-wide methylome enrichment platform was recently clinically validated for predicting and surveilling for recurrence in patients with head & neck cancer and published in Annals of Oncology. Adela's investors are F-Prime Capital, OrbiMed, Deerfield Management, Decheng Capital, RA Capital Management and Labcorp. Find more information at 1 Princess Margaret Cancer Centre, University Health Network, Toronto, Canada View original content to download multimedia: SOURCE Adela Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Los Angeles Times
25-05-2025
- Entertainment
- Los Angeles Times
Red sauce recipes for cooking like Nonna (or the one you wish you had)
Grandmothers are having a moment. The debut of the Netflix movie 'Nonnas' (Italian-ish for 'grandmothers') has people talking about grandmothers, and appreciating them not just for their home cooking, but for their brand of unconditional love wherein you're gazed at adoringly even after eating the entire bag of zeppole you were sent to the store to bring home. 'Nonnas,' based on the true story of a man who opens a restaurant in Staten Island to honor his mother and grandmother, captures a seemingly universal fantasy: a warm home where any potential problems are drowned out by love, laughter and a plate — or a buffet — of familiar, comforting foods: a casserole dish of lasagna; a pot of sausage and peppers; platters piled with meatballs, zucchini swimming in olive oil, and chunks of focaccia; extra tomato sauce (aka 'red sauce' or 'gravy'); a cut crystal bowl of parmesan; and platters of Italian cookies — straight from the heart and hands of the person who loves us most in the world. The promise of the nonna is not just the food. It's that love. I did not have this kind of grandmother. My grandmother Adela, on my dad's side, didn't cook — nor look at me adoringly as far as I remember. My grandmother Birdie, on my mom's side, cooked exactly one thing: oatmeal! Safe to say neither of them loved me more than anyone else in the world. For those of us who didn't grow up with the real deal, the fantasy of the forgiving nonna is still appealing. And for those who did, forget about it. My friend Toni Vartanian (né DiSanti) said she bawled through the opening scene, remembering Sundays at her grandparents' house in San Diego's Little Italy, with her parents, five uncles, all their wives, and three or four cousins from each pair. The women, she recalled, 'pulled out the pots and pans and made music and danced in the kitchen.' Sign me up! There's a popular saying that there are two kinds of people in the world: Italians, and those who wish they were Italian. After watching 'Nonnas,' I might amend the saying to: There are two kinds of Americans: Italian-Americans, and those who wish they were Italian-American. At least on Sundays. 'Nonnas' has been No. 1 on Netflix's list of 'Global Top 10 Movies' since it debuted on Mother's Day, with over 15 million viewers to date. The movie is also an homage to Italian-American cuisine, which has been having its moment now for a decade. In the 1990s, regional Italian cuisine, and Cal-Ital, eclipsed the red-sauce-heavy Italian food we grew up eating, whether it was served to us by a nonna or we experienced it at a checkered-tablecloth restaurant with wicker-covered wine-bottle candelabras. But we've returned to comforting Italian-American favorites; it was as if we all went on a collective exotic vacation only to come back with a new appreciation for the joys of home. Spaghetti and meatballs, garlic bread, lasagna, anything with ricotta cheese, and red sauce have reappeared at restaurants all over town. And the good news is, these dishes, which many might have seen as one-note, have been reimagined, using different (but not necessarily more difficult) cooking techniques and better ingredients. In 'Nonnas,' the film's star, played by Vince Vaughn, goes through the movie searching for the secret to his nonna's gravy. But all along, we know that the real secret to the sauce won't be found in a missing ingredient. The secret ingredient is his grandmother's love, and his memory of the feeling of being in the bosom of his family's home. And those of us who don't have that memory can get in the kitchen and make new memories. Whatever you decide to cook, just be sure to do as Nonna instructs and, 'Put in your heart.' Eating out this week? Sign up for Tasting Notes to get our restaurant experts' insights and off-the-cuff takes on where they're dining right now. These meatballs — recipe courtesy of the author's nonna — are made with a combination of beef and Italian sausage and simmered in tomato sauce, making for light, tender, flavorful meatballs. Put them in a sandwich, enjoy them on their own, with Butter Garlic Bread (see below) for sopping up the sauce, or serve them on top of spaghetti. There's plenty of sauce (here referred to as 'tomato gravy') in this recipe for that, the time: 3 hours. Serves 4. Thick loaves of white bread topped with a golden layer of garlicky butter is a must to soak up whatever flavors await at the table, or to act as a raft for meatballs, sausage, caponata or whatever other flavors await at the table. IMO, twice as much butter and olive oil wouldn't be too much. But (as the saying goes) I'm not a the time: 15 minutes. Serves 6 to 8. When I wrote a pasta cookbook for two women in Sicily and mentioned one morning that in America, we ate spaghetti with meatballs, they gasped! What do you mean 'with?' They asked. 'The meatballs are on top of the spaghetti?' Meatballs are a side dish in Italy, but in America, two or three of the savory, juicy balls sitting on top of a bowl of spaghetti, the whole story dressed in red sauce, is part of the American the time: 1 ½ hours. Serves 4 to 6.
Yahoo
12-04-2025
- Health
- Yahoo
Adela's Co-Founder & Chief Scientific Officer, Dr. Daniel De Carvalho, Receives 2025 Canada Gairdner Momentum Award Recognizing World-Renowned Scientists for Exceptional Scientific Research Contributions with Continued Potential for Impact on Human Health
The Canada Gairdner Awards celebrate the world's best biomedical and global health researchers FOSTER CITY, Calif., April 11, 2025 /PRNewswire/ -- Adela, Inc. is proud to announce that Daniel De Carvalho, PhD, Co-Founder and Chief Scientific Officer, has been honored with the prestigious Peter Gilgan Canada Gairdner Momentum Award recognizing his outstanding scientific contributions, including early breakthroughs in methylation and the discovery of Adela's best-in-class technology for blood-based cancer testing. Dr. De Carvalho's contributions have the potential to transform cancer screening and surveillance by enabling earlier detection of many new and recurrent cancers with a blood test, resulting in more effective treatment. The Canada Gairdner Awards recognize outstanding researchers whose unique scientific contributions have increased the understanding of human biology and disease. Since 1957, 426 awards have been bestowed on laureates from over 40 countries, and of those awardees, 102 have gone on to receive Nobel Prizes. The Gairdner Foundation is recognizing Dr. De Carvalho as a global leader in cancer epigenetics, immunotherapy, and liquid biopsy research for "the ground-breaking discovery of the role of transposable elements in regulating anti-tumour immunity through viral mimicry, which holds transformative potential for cancer therapy, and for pioneering the development of a novel blood-based test for early cancer detection, classification, and therapy monitoring." The novel approach to blood-based cancer detection, discovered by Dr. De Carvalho at University Health Network's Princess Margaret Cancer Centre, overcomes a significant challenge in the field - isolating genomic material for sequencing. Dr. De Carvalho's approach specifically isolates the information-rich (methylated) regions of the genome through a high-affinity enrichment process, allowing efficient capture of extensive, biologically-relevant genomic information. This advancement allows a single platform to be applied across many use cases in cancer, and also enables greater opportunity to detect cancer signals in the blood compared to other technologies that target a smaller set of genomic regions. Adela is developing the technology for minimal residual disease (MRD) monitoring and multi-cancer early detection (MCED). "We congratulate Daniel on this tremendous honor recognizing his profound contributions to the field of cancer research," said Lisa Alderson, CEO of Adela. "Daniel's discoveries have the potential to improve the lives of the millions of people impacted by cancer each year. We are excited to take these breakthrough innovations forward with the development of Adela's genome-wide methylation platform to improve the diagnosis and management of cancer." About Adela Adela is developing best-in-class technology to accelerate the diagnosis and improve the management of cancer through blood tests for minimal residual disease (MRD) monitoring and multi-cancer early detection (MCED). Adela's blood-based, tissue-free product ensures universal accessibility to MRD testing for patients with cancer, eliminating any dependency on tumor tissue availability. Adela's approach efficiently captures extensive, biologically-relevant genomic information from the methylome, providing greater opportunity to detect cancer signals in the blood compared to platforms that target a smaller set of genomic regions. Adela's first product utilizing this genome-wide methylome enrichment platform was recently clinically validated for predicting and surveilling for recurrence in patients with head & neck cancer and published in Annals of Oncology. Adela's investors are F-Prime Capital, OrbiMed, Deerfield Management, Decheng Capital, RA Capital Management and Labcorp. Find more information at View original content to download multimedia: SOURCE Adela Sign in to access your portfolio
